J. Kienast

发表

Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.

W. Berdel, H. Serve, I. Matsumura, 2000, Blood.

Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage

R. Lorenz, J. Kienast, Ulrich Otto, 2003, European journal of gastroenterology & hepatology.

Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.

J. Tchinda, W. Hiddemann, T. Haferlach, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

C. Straka, W. Berdel, A. Heinecke, 2003, British journal of haematology.

Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.

W. Berdel, H. Serve, I. Matsumura, 2000, Blood.

Flt 3 mutations from patients with acute myeloid leukemia induce transformation of 32 D cells mediated by the Ras and STAT 5 pathways

W. Berdel, H. Serve, I. Matsumura, 2000 .

Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.

W. Berdel, H. Serve, J. Kienast, 2000, Blood.

Treatment of older patients with AML.

W. Hiddemann, T. Haferlach, S. Schnittger, 2005, Critical reviews in oncology/hematology.

High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome—Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

N. Schmitz, A. Hunter, C. Kyriakou, 2008 .

Immunotherapy of B-cell malignancies with genetically engineered human CD8+ natural killer T cells

T. Tedder, S. Duwe, C. Rossig, 2006, Leukemia.

Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography.

O. Schober, C. Franzius, C. Bremer, 2008, Blood.

Generation of Melanoma-Specific Cytotoxic T Lymphocytes for Allogeneic Immunotherapy

W. Berdel, J. Schultze, J. Kienast, 2003, Journal of immunotherapy.

Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients.

V. Armstrong, G. Ehninger, M. Shipkova, 2002, Transplantation proceedings.

Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries.

H. Scheld, W. Berdel, D. Hammel, 1999, Atherosclerosis.

Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors

W. Berdel, H. Serve, C. Müller-Tidow, 2006, Molecular Cancer Therapeutics.

Successful emergency reversal of phenprocoumon anticoagulation with prothrombin complex concentrate: a prospective clinical study

R. Lorenz, J. Kienast, Ulrich Otto, 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

G-CSF/SCF reduces inducible arrhythmias in the infarcted heart potentially via increased connexin43 expression and arteriogenesis

G. Breithardt, P. Kirchhof, J. Stypmann, 2006, The Journal of experimental medicine.

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

W. Siegert, A. Zander, G. Ehninger, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evidence of Angiogenesis in Acute Myeloid Leukemia

W. Böcker, W. Berdel, T. Büchner, 2001 .

Principles of perioperative coagulopathy.

P. Innerhofer, J. Kienast, 2010, Best practice & research. Clinical anaesthesiology.

Differential Requirement for a Cellular Type-1 Immune Response in Tumor-Associated Versus Alloantigen-Targeted GvT Effects

C. Poremba, W. Berdel, J. Kienast, 2007, Transplantation.

Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions

C. Schwaenen, W. Berdel, J. Kienast, 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.

H. Büller, P. Close, J. Bichler, 1993, Journal of the American College of Cardiology.

High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

N. Schmitz, A. Hunter, C. Kyriakou, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transforming Activity of Flt3 in 32D Cells

W. Berdel, H. Serve, T. Büchner, 2001 .

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

W. Hiddemann, N. Kröger, P. Dreger, 2012, The Lancet. Oncology.

Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial

W. Hiddemann, K. Spiekermann, E. Holler, 2011, Haematologica.

Older Age Is An Independent Risk Factor in AML

W. Hiddemann, T. Haferlach, K. Spiekermann, 2008 .

Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.

W. Berdel, M. Sauerland, A. Heinecke, 2005, Blood.

CD34+ lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT

J. Gerss, F. Rosenow, W. Berdel, 2013, Bone Marrow Transplantation.

Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies

H. Einsele, H. Oettle, D. Niederwieser, 2003, Annals of Hematology.

Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor

W. Siegert, G. Ehninger, K. Höffken, 2003, Bone Marrow Transplantation.

Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities?

W. Berdel, J. Kienast, G. Bisping, 2003 .

Another dangerous traveler in myeloma blood

W. Berdel, J. Kienast, 2005 .

Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).

M. Verstraete, P. Close, J. Bichler, 1994, Coronary artery disease.

Simultaneous immunomagnetic CD34+ cell selection and B-cell depletion in peripheral blood progenitor cell samples of patients suffering from B-cell non-Hodgkin's lymphoma.

E. Hilgenfeld, W. Berdel, H. Serve, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Efficacy and Safety of Simultaneous Immunomagnetic CD 34 1 Cell Selection and Breast Cancer Cell Purging in Peripheral Blood Progenitor Cell Samples Used for Hematopoietic Rescue after High-Dose Therapy 1

E. Thiel, E. Hilgenfeld, W. Berdel, 2000 .

Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.

E. Thiel, E. Hilgenfeld, W. Berdel, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Improvement of tumor cell depletion by combining immunomagnetic positive selection of CD34-positive hematopoietic stem cells and negative selection (purging) of tumor cells

J. Kienast, W. Berdel, M. Mohr, 1999, Bone Marrow Transplantation.

adenylate cyclase activity human platelets by simultaneous modulation of phospholipase C and Sodium fluoride mimics effects of both agonists and antagonists on intact

J. Arnout, H. Deckmyn, J. Vermylen, 2011 .

Sodium fluoride mimics effects of both agonists and antagonists on intact human platelets by simultaneous modulation of phospholipase C and adenylate cyclase activity

H. Deckmyn, J. Vermylen, J. Kienast, 1987 .

Sodium fluoride mimics effects of both agonists and antagonists on intact human platelets by simultaneous modulation of phospholipase C and adenylate cyclase activity.

J. Arnout, H. Deckmyn, J. Vermylen, 1987, Blood.

Summary The catalytic domain of endogenous urokinase-type plasminogen activator is required for the mitogenic activity of platelet-derived and basic fibroblast growth factors in human vascular smooth muscle cells

W. Berdel, J. Kienast, M. Kiehl, 2022 .

Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia

H. Serve, C. Müller-Tidow, T. Büchner, 2002, Leukemia.

hematopoietic stem cell transplantation in acute myeloid leukemia Conditioning with 8 Gy total body irradiation and fludarabine for allogeneic

W. Berdel, A. Heinecke, T. Büchner, 2013 .

Bortezomib in combination with intermediate‐dose dexamethasone and continuous low‐dose oral cyclophosphamide for relapsed multiple myeloma

H. Einsele, N. Kröger, O. Sezer, 2007, British journal of haematology.

Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.

C. Poremba, W. Berdel, E. Oelmann, 2004, Blood.

Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD 8 + T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets Running title : Tumor specific GvT reaction is driven by GvHD

C. Poremba, W. Berdel, E. Oelmann, 2004 .

Transplantation in Hematology and Oncology

H. Jürgens, T. Büchner, J. Ritter, 2000, Springer Berlin Heidelberg.

Factors affecting the efficacy of peripheral blood progenitor cells collections by large‐volume leukaphereses with standardized processing volumes

J. Kienast, W. Sibrowski, J. Vormoor, 2004, Transfusion.

Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial

H. Einsele, A. Zander, J. Finke, 2011, Haematologica.

Early Tandem High-Dose Ifosfamide, Carboplatin, Etoposide Therapy with Stem Cell Rescue for Small-Cell Lung Cancer: Brief Report on the Results of a Phase-I/II Trial

H. Serve, M. Thomas, E. Oelmann, 2002, Oncology.

Prediction of relapse of acute myeloid leukemia in allogeneic transplant recipients by marrow CD34+ donor cell chimerism analysis

J. Tchinda, J. Kienast, M. Zuehlsdorf, 2004, Leukemia.

Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin

S. Opal, J. Briegel, J. Kienast, 2006, Thrombosis and Haemostasis.

Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation

S. Opal, J. Kienast, H. Ostermann, 2006, Journal of thrombosis and haemostasis : JTH.

Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders.

G. Schmitz, J. Kienast, 1990, Blood.

Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma.

W. Berdel, J. Kienast, R. Mesters, 2003, Blood.

Enhanced Anti-Myeloma Activity by Combination of Receptor Tyrosine Kinase (RTK) Inhibition, Proteasome Inhibition, and Dexamethasone: Therapeutic Implications for t(4;14) and t(14;16) Multiple Myeloma (MM) Subgroups.

W. Berdel, F. Hilberg, J. Kienast, 2005 .

An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma.

W. Berdel, B. Gaschler-Markefski, J. Kienast, 2009, Anticancer research.

Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3–Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma

W. Berdel, C. Müller-Tidow, F. Hilberg, 2009, Clinical Cancer Research.

Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study

N. Kröger, G. Ehninger, H. Wandt, 2006, European journal of haematology.

Cytogenetically normal acute myeloid leukemia.

W. Berdel, T. Büchner, J. Kienast, 2008, The New England journal of medicine.

Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups.

J. Tchinda, W. Berdel, H. Serve, 2006, Blood.

induction of apoptosis in cytogenetically defined subgroups myeloma: abrogation of stroma-derived interleukin-6 secretion and Targeting receptor kinases by a novel indolinone derivative in multiple

H. Serve, C. Müller-Tidow, F. Hilberg, 2013 .

Frequent gains of the short arm of chromosome 9 in multiple myeloma with normal G-banded karyotype detected by comparative genomic hybridization.

J. Tchinda, W. Berdel, F. Meinhardt, 2004, American journal of clinical pathology.

IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: A randomized, controlled, multiple-center trial*

W. Hiddemann, G. Behre, C. Salat, 2006, Critical care medicine.

Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.

W. Berdel, T. Büchner, J. Kienast, 2000, Blood.

Efficacy and safety of thalidomide in patients with acute myeloid leukemia.

W. Berdel, J. Kienast, M. Steins, 2002, Blood.

bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 20, 2013. For personal use

W. Berdel, J. Kienast, R. Mesters, 2000 .

The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation

W. Berdel, J. Kienast, M. Steins, 2005, Transfusion.

Kinetics of standardized large volume leukapheresis (LVL) in patients do not show a recruitment phenomenon of peripheral blood progenitor cells (PBPC)

J. Kienast, W. Sibrowski, M. Zuehlsdorf, 2001, Bone Marrow Transplantation.

Christoph Schmid, Hans Martin, Bernd Hertenstein, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transplantation in Hematology and Oncology II

H. Jürgens, T. Büchner, J. Ritter, 2003, Springer Berlin Heidelberg.

Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission.

V. Diehl, A. Ganser, A. Zander, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Venous thromboses in particular organs.

M. Verstraete, J. Vermylen, J. Kienast, 1986, Journal of the American College of Cardiology.

W. Hiddemann, T. Haferlach, K. Spiekermann, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer-binding protein α from hematopoietic cells in a family with AML

K. Döhner, H. Döhner, S. Koschmieder, 2011, Leukemia.

The catalytic domain of endogenous urokinase-type plasminogen activator is required for the mitogenic activity of platelet-derived and basic fibroblast growth factors in human vascular smooth muscle cells.

W. Berdel, J. Kienast, M. Kiehl, 2002, Journal of cell science.

Peripheral Blood and Bone Marrow Derived Dendritic Cells in Acute Myelogenous Leukemia

W. Berdel, H. Serve, T. Büchner, 2000 .

The German competence network ‘Acute and chronic leukemias’

W. Hiddemann, H. Döhner, A. Ganser, 2004, Leukemia.

c-maf in multiple myeloma: an oncogene enhancing tumor-stroma interactions.

W. Berdel, J. Kienast, 2004, Cancer cell.

Pros and Cons Session: Indications for Allogeneic Transplants in Chronic Leukemias

W. Siegert, A. Neubauer, C. Thiede, 2002, Annals of Hematology.

Minimal change glomerulonephritis with reversible proteinuria during interferon α2a therapy for chronic myeloid leukemia

J. van de Loo, J. Kienast, J. Kienast, 1995, American journal of hematology.

Allogeneic Cell Therapy with Antigen-Specific Cytotoxic T Lymphocytes (CTL) for Malignant Melanoma

W. Berdel, J. Kienast, A. Nolte, 2003 .

Guanine nucleotide-dependent inhibition of phospholipase C in human endothelial cells.

H. Deckmyn, J. Vermylen, J. Kienast, 1990, The Journal of biological chemistry.

Subgroup specific therapy effects in AML: AMLCG data.

W. Hiddemann, T. Haferlach, C. Schoch, 2004, Annals of hematology.

Proteasome inhibition in multiple myeloma.

W. Berdel, J. Kienast, M. Kropff, 2006, European journal of cancer.

Sodium fluoride induced activation of phospholipase C in intact human platelets does not depend on ADP, PAF or arachidonate products.

J. Arnout, H. Deckmyn, J. Vermylen, 1993, Thrombosis research.

On the role of guanine nucleotide binding regulatory proteins (G-proteins) in signal transduction in human platelets: studies with sodium fluoride (NaF).

J. Arnout, H. Deckmyn, J. Vermylen, 1986, Agents and actions. Supplements.

Thalidomide for the Treatment of Acute Myeloid Leukemia

W. Berdel, J. Kienast, M. Steins, 2003, Leukemia & lymphoma.

Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia.

W. Siegert, N. Kröger, A. Zander, 2002, Annals of hematology.

TBI-Based Reduced Intensity Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) in Patients with High-Risk Hematologic Malignancies

A. Schuck, W. Berdel, J. Kienast, 2003 .

Relation of Urokinase-Type Plasminogen Activator Expression to Presence and Severity of Atherosclerotic Lesions in Human Coronary Arteries

H. Scheld, K. Schmid, J. van de Loo, 1998, Thrombosis and Haemostasis.

Mediators in Sepsis and Septic Shock

T. Büchner, J. Kienast, M. Kiehl, 1997 .

Overexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia.

W. Berdel, J. Kienast, M. Steins, 2003, Cancer research.

Iron-oxide-enhanced MR imaging of bone marrow in patients with non-Hodgkin's lymphoma: differentiation between tumor infiltration and hypercellular bone marrow

E. Rummeny, H. Daldrup-Link, T. Link, 2002, European Radiology.

Evidence for predictive validity of blood assays to evaluate individual radiosensitivity.

N. Willich, W. Göhde, B. Greve, 2006, International journal of radiation oncology, biology, physics.

Bortezomib in Combination with High-Dose Dexamethasone and Continuous Low-Dose Oral Cyclophosphamide for Relapsed Multiple Myeloma.

H. Einsele, O. Sezer, C. Straka, 2005 .

Bortezomib in combination with dexamethasone for relapsed multiple myeloma.

J. Tchinda, W. Berdel, J. Kienast, 2005, Leukemia research.

Simultaneous Double-Purging of Breast Cancer Cells from Leukapheresis Products by Immunomagnetic CD34+ Cell Enrichment and Tumor Cell Depletion

E. Thiel, E. Hilgenfeld, W. Knauf, 2000 .

High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: Efficacy and safety*

S. Opal, J. Briegel, J. Kienast, 2006, Critical care medicine.

Volume-controlled versus biphasic positive airway pressure ventilation in leukopenic patients with severe respiratory failure.

J. Kienast, M. Kiehl, W. Stenzinger, 1996, Critical care medicine.

Myeloma: targeted therapies march on

J. Kienast, M. Kropff, 2004 .

The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation

A. Nagler, D. Niederwieser, T. Witte, 2008, Bone Marrow Transplantation.

Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry.

M. Olschewski, A. Geibel, J. Kienast, 1997, Journal of the American College of Cardiology.

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

S. Thompson, J. van de Loo, J. Kienast, 1995, The New England journal of medicine.

Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: relation to stroke etiology.

E. Ringelstein, J. Kienast, J. Kienast, 1999, Neurological research.

Increase of Plasminogen Activator Inhibitor Levels Predicts Outcome of Leukocytopenic Patients with Sepsis

J. Kienast, J. Kienast, H. Ostermann, 1996, Thrombosis and Haemostasis.

Inflammatory mediators in BAL fluid as markers of evolving pneumonia in leukocytopenic patients.

J. Kienast, M. Kiehl, T. Birkfellner, 1997, Chest.

Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry.

M. Olschewski, H. Just, A. Geibel, 1997, Circulation.

73 POSTER Pharmacokinetic characterization of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in advanced cancer patients

R. Kaiser, I. Judson, J. Kienast, 2006 .

Comparative analysis of plasminogen activator inhibitor-1 expression in different types of atherosclerotic lesions in coronary arteries from human heart explants.

H. Scheld, J. Kienast, D. Hammel, 1997, Cardiovascular research.